Quotient Clinical Receives MHRA Supplementary Accreditation
News Jul 10, 2009
Quotient Clinical has announces that it has been awarded Supplementary Accreditation from the Medicines and Healthcare products Regulatory Agency (MHRA).
This is one of the highest levels of accreditation in Europe and confirms that Quotient Clinical is qualified to perform the full range of Phase I trials, including First-in-Human (FIH) studies for low molecular weight chemical entities and biologics.
The MHRA voluntary accreditation scheme was introduced in April 2008 in line with recommendations from the MHRA clinical trial expert advisory group, to maximize subject safety, and provides formal guidance on the standards expected in a clinical unit conducting FIH studies.
Mark Egerton, Managing Director of Quotient Clinical comments, “Our MHRA Supplementary Accreditation provides volunteers and sponsors with additional reassurance of the high standards we apply in performing clinical studies. This award acknowledges our continued commitment to quality and safety and underpins our status as one of the leading clinical units in Europe.”
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
CBD Significantly Reduces Seizures in Patients with Severe Form of EpilepsyNews
Large-scale clinical trial finds cannabidiol can dramatically reduce the number of dangerous seizures in patients with a severe form of epilepsy called Lennox–Gastaut syndrome.
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018